Huntingdon Business Making an Impact on Pedestrian Safety Worldwide


Friday 8 February 2019



Cellbond, Huntingdon-based developers and manufacturers of vehicle passive safety test equipment, have received a massive boost to their business after consumer organisation, EuroNCAP, approved one of their products for use in tests involving all new vehicles in Europe from 2022 / 2023.

The Advanced Pedestrian Legform Impactor (aPLI) represents a pedestrian leg during collision with a vehicle. The decision by Euro NCAP implies that it will be used by all major vehicle manufacturers world-wide to develop safer vehicles, as well as by test labs working for Euro NCAP to establish individual vehicle safety ratings.

The Cellbond team have been working on the aPLI project since 2016 in collaboration with an international working group. There was strong competition from a US-led project, however, Cellbond’s design was found to be more effective following global comparison tests. It is expected that other road safety organisations will follow Euro NCAP’s lead over the next few months and specify Cellbond’s aPLI for use in their tests, opening up the market in the USA, China, Japan, Korea, Taiwan, India, and Australia.

Dr Mike Ashmead, Founder and Chairman of Cellbond, said: “We are delighted to be able to make such a significant contribution to the future of pedestrian safety. Our team has worked tirelessly to develop and produce a biofidelic leg which accurately represents a real-life pedestrian and we are very pleased with the feedback from Euro NCAP and our colleagues in the industry.”

Serial production of the aPLI is now underway in Cellbond’s Stonehill manufacturing plant. “The future looks bright with steady growth in employees and turnover for Cellbond,” Dr Ashmead added, “and we are already working on the next innovations which will enhance our product portfolio and support the Automotive Industry worldwide.”